Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5293402 | 0.81 | MAPT (0.43) | SLC6A2SLC6A3CYP2D6SLC6A4TAAR1 | |
| SCHEMBL30567467 | 0.80 | ALDH1A1 (0.52) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL85405 | 0.80 | ALDH1A1 (0.52) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL11670010 | 0.77 | ALDH1A1 (0.52) | CYP2D6CYP3A4MAPTALDH1A1MEN1 | |
| SCHEMBL14349288 | 0.77 | CYP3A4 (0.45) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL8284590 | 0.77 | CYP3A4 (0.45) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL933157 | 0.77 | CYP3A4 (0.50) | SLC6A2SLC6A3CYP3A4TRPV1MAPT | |
| SCHEMBL22338921 | 0.77 | CYP3A4 (0.45) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL20222611 | 0.77 | CYP3A4 (0.45) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 | |
| SCHEMBL5288474 | 0.77 | CYP3A4 (0.45) | SLC6A2SLC6A3SLC6A4TAAR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | claimed |
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | Eagle Research Labs Limited (MT) | 2022-06-07 | — | — | US | disclosed |
| US-20210236467-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | EAGLE PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3796889-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | Eagle Pharmaceuticals, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20210015796-A1 | TREATMENT USING DANTROLENE | LYOTROPIC THERAPEUTICS INC (US) | 2021-01-21 | — | — | US | disclosed |
| EP-1603513-B1 | DANTROLENE COMPOSITIONS | LYOTROPIC THERAPEUTICS INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10821098-B2 | Treatment using dantrolene | LYOTROPIC THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3697779-A1 | DANTROLENE PRODRUGS AND METHODS OF THEIR USE | EAGLE RESEARCH LABS LIMITED (MT) | 2020-08-26 | — | — | EP | disclosed |
| US-20200239455-A1 | DANTROLENE PRODRUGS AND METHODS OF THEIR USE | Eagle Research Labs Limited | 2020-07-30 | — | — | US | disclosed |
| CN-111344286-A | Dantrolene prodrugs and methods of use thereof | 伊格尔研究实验室有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-8110225-B2 | Treatment using dantrolene | LYOTROPIC THERAPEUTICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-7758890-B2 | Treatment using dantrolene | LYOTROPIC THERAPEUTICS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100160400-A1 | TREATMENT USING DANTROLENE | LYOTROPIC THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| EP-1603513-A2 | TREATMENT USING DANTROLENE | Lyotropic Therapeutics, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005013919-A2 | TREATMENT USING DANTROLENE | LYOTROPIC THERAPEUTICS, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040242646-A1 | Dantrolene as anesthetics for pumping injection | LYOTROPIC THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-5411965-A | Use of delta opioid receptor antagonists to treat cocaine abuse | ARIZONA BOARD OF REGENTS (US) | 1995-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | SLC6A2 97/4885SLC6A3 36/4885CYP2D6 547/4885 |
| US-20200239455-A1 | DANTROLENE PRODRUGS AND METHODS OF THEIR USE | BID, TPMT, CES2 | SLC6A2 1224/4885SLC6A3 680/4885CYP2D6 62/4885 |
| US-20210236467-A1 | DANTROLENE FORMULATIONS AND METHODS OF THEIR USE | SMN1; SMN2, LIPA, LCLAT1 | SLC6A2 88/4885SLC6A3 39/4885CYP2D6 827/4885 |
| US-11352347-B2 | Dantrolene prodrugs and methods of their use | BID, TPMT, CES2 | SLC6A2 1224/4885SLC6A3 680/4885CYP2D6 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.